General anaesthesia for laparotomy
Conditions
Interventions
closed-loop control group:closed-loop control of propol infusion guided by BIS
Sponsors
Anaesthesia Department, Westchina Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged between 18 to 65 years; 2. ASA grade level I ~ III; 3. estimated operation time >=2 hours.
Exclusion criteria
Exclusion criteria: 1. Comorbidity of cerebrovascular epilepsy or other neurological diseases; 2. have mental illness, recent psychiatric drug therapy; 3. with alcohol, opioids or other psychotropic substance abuse history; 4. difficult airway risks exist or for any other reason, can not receive conventional intravenous induce; 5. propofol allergy; 6. severe cardiovascular disease, liver andkidney function was abnormal; 7. albumin level abnormal; 8. BMI=30; 9. can not provide informed consent; 10. drug use of liver enzyme inducers or inhibitors one month preoperative. Common hepatic drug metabolizing enzyme inducers including barbiturates, carbamazepine, rifampicin, dexamethasone, ethanol (chronic alcoholism), griseofulvin, phenytoin class; common hepatic drug metabolizing enzyme inhibitors including chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid andsulfa drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Propofol dosage during anesthesia maitenance period;UGT1A9 1399C> T andCYP2B6c.516G> T single nucleotide polymorphism; | — |
Secondary
| Measure | Time frame |
|---|---|
| propofol dosage required to reach a BIS level below 60 during induction period;percent of maitanence time with BIS value between 40 to 60;interval from stopping using propofol to opening eyes andextubation;dosage of remifentanyl during maintenance period;Perioperative hemodynamic andvasoactive drug use;The performance parameters of the closed-loop control system (performance error, median performance error, median absolute performance error, wobble andGS);incidence of intraoperative awareness andother serious adverse events; | — |
Countries
China
Contacts
Public ContactZuo Yunxia
Outcome results
None listed